CA-CEPTON-TECHNOLOGIES
Cepton Technologies (“Cepton”), an innovative provider of smart lidar solutions , and Vortex IoT (“Vortex”), a UK-based IoT solutions company, have combined their skills to turn UK buses into real-time road inspection tools, enabling a lidar-based vehicle to infrastructure (V2I) solution for urban asset management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005421/en/
Vortex’s award-winning lidar-powered Continuous Urban Scanner System (CURBS ) enables asset and infrastructure management by identifying certain situations such as pot-holes, surface damage and roadside defects in real time by using 5G wireless technology to transmit the data to road management teams.
This solution uses artificial intelligence and machine learning alongside Cepton’s Vista®-P60 high-resolution lidar sensors to create a detailed map of the urban environment. This is done by retrofitting the CURBS product to vehicles to create a real-time 3D scanning and dynamic monitoring system. Mounted on public transportation, such as bus fleets, refuse collection trucks and mobile enforcement vehicles, the lidar-embedded CURBS product is able to pinpoint areas that may need repair to maintenance teams, allowing for the early identification of issues.
CURBS streams the processed information over 5G networks. Crucially, this information helps to not only provide real-time insights to services such as road maintenance, but also to drive intelligent decisions with the goal of optimizing traffic management, such as enabling preventive measures in accident-prone areas and improving the efficiency of traffic. These anticipated improvements are intended to ultimately help drive down carbon emission while making cities safer and smarter.
A pilot for the solution is currently underway in the West Midlands in a UK Government-sponsored 5G program called “WM5G”, where Vortex has partnered with National Express and BT.
“The mission of the WM5G Transport team is to support 5G innovation within the region to make transport networks safer, more sustainable and more intuitive to users,” said David Conner, Project manager at WM5G Transport. “The CURBS project is a great example of how the West Midlands is leading the way nationally in making our cities smarter and better connected. By enabling powerful connectivity to transfer large amounts of lidar and camera data, 5G supports the generation of 3D maps capable of providing the insights required to enhance road safety and guide the development of smart cities.”
Vortex also has additional deployments scheduled with traffic enforcement and smart city management company, Marston Holdings.
“With vehicles becoming increasingly smarter, city infrastructure also demands next-generation innovations to deliver matching intelligence. Smart city solutions like CURBS are set to become commonplace across our towns and cities,” said Adrian Sutton, co-founder and CEO at Vortex.
“Public authorities need efficient, scalable ways to manage urban environments, and this becomes even more important as the focus on issues such as decarbonization, sustainability and climate change grows.”
“At the heart of this is digital transformation and the potential that connected technologies and data analytics present for asset management in real time. Enhanced use of big data will drive rapid urban planning and dynamic decision making. Here, perception is key, and nothing can produce accurate 3D data in real-life urban environments quite like lidar – especially the state-of-the-art lidar solutions developed by Cepton, which combine high resolution and long range while enabling sensor robustness and reliability, making their sensors ideally suited for these types of applications.”
CURBS leverages a number of benefits through its use of Cepton’s Vista-P60 sensors . Firstly, the lidars perform with accuracy and resilience in a variety of weather and lighting conditions. In contrast, cameras need sufficient light to be effective and can be blinded by strong light. Because cameras provide only two-dimensional imaging typically with no accurate size and location data, they need additional computing resource to process the image to extract useful information, which might take up more bandwidth and lead to lag.
Secondly, lidar data is completely anonymized , protecting the privacy of citizens and eliminating the need for additional data management and security protocols. Lidar collects no biometric data, making individual features unidentifiable from lidar point cloud visualizations.
Finally, the Vista-P60 lidars, powered by Cepton’s patented Micro Motion Technology (MMT®), are non-rotational, mirrorless and frictionless . This makes it possible for the sensor to deliver high performance while offering a low-power and compact solution to help drive down integration and maintenance costs. The scalability of the Vista-P60 lidars make them ideal for V2I smart city applications like CURBS.
Dr. Jun Pei, CEO at Cepton, explained: “Advanced sensor technologies have played an increasingly important role in the development of safe, accurate and intelligent transportation systems . Using our MMT-based lidar solutions, we are pleased to partner with Vortex to enable CURBS to achieve its mission of helping towns and cities across the world become safer, greener and more efficient for all.”
Cepton will participate in the upcoming ITS World Congress 2021 in Hamburg, Germany from October 11th to 15th . To learn more about Cepton’s partnership with Vortex and its lidar solutions for smart cities applications, please visit booth B7-135 .
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
About Vortex IoT
Vortex is a young, dynamic and market-leading company at the forefront of smart city technologies. The company builds environmental sensors, networks and data solutions to support decarbonisation efforts globally. As experts in the latest IoT, AI, 5G and LiDAR technology, Vortex enables smart cities & smart infrastructures to become more efficient, safer and greener.
Monitor what matters; Act where it counts. Vortex's sensor technology aims to maximize visibility and delivers the actionable data that businesses need to start making smarter decisions. Air Quality Monitoring, Vehicle-2-Infrastructure Scanning, Remote Infrastructure Management and Smart Parking Systems are Vortex's tailored solutions for progressive smart city management. Powered by AI and enabled by a highly secure decentralised mesh network, all of Vortex’s products guarantee reliability, scalability and environmentally sustainable deployments.
Founded upon a bedrock of innovation, Vortex’s highly skilled team of engineers, technologists and leadership team are constantly developing the eco-smart products of tomorrow, for you today. For more information, please visit www.vortexiot.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005421/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
